TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
LA JOLLA, Calif., June 23, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.
About TorreyPines Therapeutics
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.
Company Contact: Media Contact: Paul Schneider David Schull TorreyPines Therapeutics, Inc. Russo Partners, LLC 858-623-5665, x125 212-845-4271 firstname.lastname@example.org email@example.com Investor Contact: Rhonda Chiger Rx Communications 917-322-2569 firstname.lastname@example.org
CONTACT: Paul Schneider of TorreyPines Therapeutics, Inc.,+1-858-623-5665, ext. 125, ; ormedia, David Schull of Russo Partners, LLC, +1-212-845-4271,; or investors Rhonda Chiger of RxCommunications, +1-917-322-2569, , both for TorreyPinesTherapeutics, Inc. email@example.com firstname.lastname@example.org email@example.com
Web site: http://www.torreypinestherapeutics.com/
Ticker Symbol: (NASDAQ-NMS:TPTX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2008